We demonstrate that the microtubule-associated protein tau, in the form of enhanced green fluorescent protein (EGFP) tau, is transported along axons of neurons in culture in the slow component of axonal transport with a speed comparable with that previously measured in vivo. It was demonstrated that the EGFP tag has no effect on transport characteristics, and the methodology enables slow transport rates of individual tau isoforms and tau mutants to be measured. We also expressed EGFP-tagged tau isoforms containing either three or four C-terminal repeats and zero or two N-terminal inserts in cultured neurons. No significant differences were found in the average rate of slow transport of the wild-type tau isoforms, suggesting that the exon 10 C-terminal repeat or the N-terminal inserts do not contain regions that play a significant regulatory role in axonal transport. Similarly, we found that missense mutations in tau have no noticeable effect on the rate of transport; hence their ability to cause neurodegeneration is by another mechanism other than that affecting the overall slow axonal transport of tau.
The axonal transport of components synthesized in the cell body through the axon is classified as fast transport, with rates up to several hundred millimeters per day, and slow transport, moving at rates of ϳ1 mm/d in slow component a and several millimeters per day in slow component b (Baas and Brown, 1997; Hirokawa et al., 1997; Nixon, 1998) . The axonal transport of the microtubuleassociated protein tau has been assessed by in vivo methods; reported rates vary between 0.2 and 0.4 mm/d in retinal ganglion cells and between 1.7 and 3 mm/d for sciatic nerve (Tytell et al., 1984; Mercken et al., 1995; Tashiro et al., 1996) .
Tau in human brain consists of six isoforms, differing in the absence or presence of zero, one, or two N-terminal inserts and either three or four C-terminal repeat regions (Francon et al., 1982; Goedert et al., 1989; Goedert and Jakes, 1990 ). The C terminus of tau contains the microtubule-binding regions, regulating microtubule dynamic properties (Lee and Rook, 1992; Brandt and Lee, 1993; Léger et al., 1994) , and the N terminus of tau has been shown to interact with the neuronal plasma membrane (Brandt et al., 1995; Maas et al., 2000) . We now have compared the rates of transport of individual tau isoforms by the direct method of monitoring the movement of enhanced green fluorescent-labeled (EGFP) tau by a previously successful technique that was used for studying the middle neurofilament subunit NF-M (Ackerley et al., 2000) .
The mechanisms of conversion of tau from a functional microtubule-associated protein to an aggregated form in many neurodegenerative diseases are still mainly unknown. Tau also is known to redistribute from its primary location in the axon to the somatodendritic compartment in disease (Götz et al., 1995) . Recent reports suggest that in cultured neurons the overexpression of tau impairs the axonal transport of components such as mitochondria and neurofilaments (Stamer et al., 2002) and that fast axonal transport also may be impaired in transgenic animals overexpressing tau (Ishihara et al., 1999) . It is also possible that A␤ may impair in vivo the axonal transport of tau itself (Götz et al., 2001) .
Tau dysfunction leading to neurodegeneration has been demonstrated unequivocally with the identification of mutations in tau in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998) . The mechanisms by which these mutations lead to neurodegeneration are far from clear. Some of the missense mutations have been shown to have a reduced binding to microtubules (Hasegawa et al., 1998; Hong et al., 1998; Dayanandan et al., 1999; Rizzu et al., 1999; Barghorn et al., 2000) , to increase the tendency of tau to aggregate in vitro Nacharaju et al., 1999; von Bergen et al., 2001) and in vivo (Vogelsberg-Ragaglia et al., 2000) , and to decrease tau degradation . From these studies it is clear, however, that not all of the missense mutations affect the function of tau in same manner. This suggests that as yet undiscovered mechanisms may be occurring.
To address this, we describe the first direct measurements of axonal transport of various wild-type and mutant forms of tau by directly monitoring EGFP-tagged tau that has been transfected into rat cortical neurons in culture.
MATERIALS AND METHODS
Constructs. All tau constructs (wild type and mutants) prepared for cloning into EGFP vectors were amplified by using primers with SalI and BglII linkers for directional restriction cloning into pEGFP-C1 (EGFP f used to the N terminus of tau; C lontech Laboratories, Basingstoke, UK). Site-directed mutagenesis was used to introduce the tau mutations as described by Dayanandan et al. (1999) . The tau mutations introduced into 0N3Rtau (0 N-terminal insert, 3 C -terminal repeat tau isoform) were V337M (valine-to-methionine mutation at position 337) and R406W (arginine-to-tryptophan mutation at position 406). The tau mutations introduced into 0N4Rtau (0 N-terminal insert, 4 C -terminal repeat tau isoform) included the following: I260V (isoleucine-to-valine mutation at position 260), delK280 (deletion of lysine residue at position 280), P301L (proline-to-leucine mutation at position 301), V337M (valine-to-methionine mutation at position 337), and R406W (arginineto-tryptophan mutation at position 406).
DNA for transfection was prepared by an endotoxin-free Maxiprep kit (Qiagen, Crawley, UK). DNA from independent maxi-preparations was used to avoid any possible batch-specific effects. 0N4Rtau also was cloned into pEGFP-N1 (C lontech Laboratories) to allow for comparison with C1 constructs. In addition, 0N4Rtau was cloned into pCIneo (Promega, Southampton, UK) to allow for comparison with the EGFP-tagged constructs.
Transfection of cortical cultures. Cortical neurons were obtained from embryonic day 18 (E18) rat embryos and cultured as described by Ackerley et al. (2000) . Briefly, 6-to 7-d-old primary cortical cells were transfected by a modified calcium phosphate method with a Profection kit (Promega) as described by Ackerley et al. (2000) (essentially according to Nikolic et al., 1996; X ia et al., 1996) . After incubation of the DNA /calcium phosphate precipitate on the neurons for ϳ40 min, the incubation was stopped by shocking with 2% (v/ v) DMSO/5% (v/ v) glycerol in H EPES-buffered saline. The cells were washed three times with culture media and returned to the incubator. To determine the requirement of metabolic energy for the transport of tau, we treated cells with 50 mM 2-deoxy-D-glucose/0.05% (v/ v) sodium azide for 30 min at 120 min after transfection shock treatment (Yoon et al., 1998) . C ells then were washed with culture media and f urther incubated to allow the cells to be fixed at given times.
Fi xation of neuronal cultures and image anal ysis. At appropriate time points after shock the neurons were fixed with 4% (w/ v) paraformaldehyde/ PBS prewarmed to 37°C for 20 min and then mounted in Vectashield (Vector Laboratories, Peterborough, UK). Neurons were examined with a Z eiss Axioskop microscope, and images were collected via a CCD camera and analyzed with MetaMorph image analysis software (Roper Scientific, Marlow, UK). The distance traveled by the tau-EGFP was measured from the perimeter of the cell body along the axon to the limit of the fluorescent front. Approximately 20 -50 neurites were analyzed per time point within a data set. The average rate of tau transport was calculated from the linear regression of each experiment and averaged from between 3 and 13 independent experiments. Statistical analysis was performed with the one-way ANOVA test.
Tau-EGFP-transfected neurons also were processed by using the following fixation /extraction /permeabilization methods (protocols based on Black et al., 1996) : procedure 1, as above; procedure 2, 4% (w/ v) paraformaldehyde/ PBS (prewarmed to 37°C) for 20 min at room temperature, followed by incubation with 0.1% (v/ v) Triton X-100/ PBS for 10 min at room temperature; procedure 3, 4% (w/ v) paraformaldehyde/ PBS (prewarmed to 37°C) for 20 min at room temperature, followed by incubation with 0.1% (v/ v) Triton X-100/ PBS for 2 min at room temperature; procedure 4, 4% (w/ v) paraformaldehyde/ PBS (prewarmed to 37°C) for 20 min at room temperature, followed by an incubation with 0.5% (v/ v) Triton X-100/ PBS for 10 min at room temperature; procedure 5 (fixation without extraction), 0.3% (v/ v) glutaraldehyde/ PEM (80 mM PI PES, 5 mM EGTA, 1 mM magnesium chloride, pH 6.8; prewarmed to 37°C) for 20 min at room temperature, followed by permeabilization with 0.5% (v/ v) Triton X-100/ PBS for 10 min at room temperature; procedure 6 (combined fixation /extraction), 0.3% (v/ v) glutaraldehyde/ PEM /0.5% (v/ v) N P-40 (prewarmed to 37°C) for 10 min at room temperature. All fixation procedures that used glutaraldehyde were subjected to the following incubations after fixation /permeabilization: 10 mg /ml sodium borohydride in PBS for 7 min, rinsed with PBS, 0.1 M glycine in PBS for 20 min, rinsed with PBS, and incubation with 1% (w/ v) blocking solution (BSA / PBS) for 30 min. All incubations were performed at room temperature.
Nocodazole treatment of transfected neurons and immunofluorescence.
At 24 hr after transfection the neurons were treated with 5 g /ml nocodazole (Tocris, Bristol, UK) for 30 min at 37°C. Neurons then were fixed by using the combined fixation /extraction procedure 6 as detailed above. Untreated and treated neurons were stained for tubulin with the DM1A antibody (Sigma, Poole, UK), followed by incubation with a Texas Red-labeled secondary antibody (Vector Laboratories).
Anal ysis of tau e xtracted f rom neurons. To assess the removal of soluble tau released from neurons when the combined fixation /extraction procedure 6 was used, we treated neurons with either PBS for 20 min or 0.5% (v/ v) N P-40/ PEM for 10 min (to mimic the extraction conditions). The solution was removed from the neurons, and total protein was precipitated by the addition of ϳ8 volumes of cold methanol (Black et al., 1996) . The resulting methanol-precipitated material was collected by centrif ugation, air-dried, and dissolved in SDS-PAGE sample buffer (Sambrook et al., 1989) . The neurons were scraped directly into SDS-PAGE sample buffer. The resulting material was analyzed by SDS-PAGE and immunoblotting with the polyclonal tau antibody TP70 (Brion et al., 1993) .
Immunofluorescence microscopy. Costaining of tau-EGFP-transfected neurons for the dendritic marker M AP2 was performed by using M AP2a / b monoclonal antibody (Sigma), followed by incubation with a Texas Red-labeled secondary antibody (Vector Laboratories). Neurons that were transfected with 0N4Rtau cloned into pCIneo were stained with a four-repeat tau-specific antibody raised to the additional repeat region present in 4Rtau [antibody raised against peptide II N K K LDL -SN VQSK , corresponding to amino acids 277-290; numbering according to htau40 (2N4Rtau, 441 amino acids) (Goedert et al., 1989) ]. The antibody was used at a concentration of 1:200 for 2 hr at room temperature, followed by incubation with a FI TC -labeled secondary antibody (Vector Laboratories).
RESULTS

Direct visualization of tau transport along axons
We have analyzed the rate of anterograde transport of tau by transfecting rat cortical neuronal cultures with tau-EGFP (Nterminally tagged) and analyzing the cells by fluorescence microscopy after fixation up to 300 min after transfection. Cells were analyzed randomly by measuring the distance traveled by the tau-EGFP from the perimeter of the cell body to the boundary of the fluorescent front along the longest neurite (also see Ackerley et al., 2000) . Representative experiments were analyzed by independent workers, and no significant difference in the distance to the fluorescent front was observed, demonstrating that the limit of the fluorescent front was identified easily. Measurements were taken up to 300 m from the cell body to avoid including neurites in which tau-EGFP had reached the neurite terminals. Previous studies have demonstrated that the average length of neurites of cortical neurons under these experimental conditions exceeded 700 m; hence the assays are of transport within the neurites and are not a reflection of neurite outgrowth rates (Ackerley et al., 2000) . Figure 1 shows representative images of 0N4Rtau-EGFP transported along the neurites; a-d show examples of neurites taken at 120, 180, 210, and 240 min after transfection shock treatment, showing an approximate travel distance from the cell body of 50, 100, 120, and 150 m, respectively. EGFP when transfected alone (data not shown) (Ackerley et al., 2000) was observed along the length of all processes at early time points, indicating a possible movement by fast axonal transport.
To analyze whether the tau fusion proteins were sorted correctly to axons after transient transfection, we costained 0N4Rtau-EGFP-transfected neurons for endogenous MAP2, a microtubule-associated protein localized to dendrites. Analysis shows that 0N4Rtau-EGFP protein was sorted to the axons (Fig.  2) . In addition, 0N4Rtau-EGFP was found to be present in the cell body and dendrites, although this is not unusual because a variety of exogenously expressed axonal proteins has been shown to exhibit this distribution either because of saturation of the axonal sorting machinery (for review, see Winckler and Mellman, 1999) or because neuronal process selectivity mechanisms downstream of transport occur at the plasma membrane as suggested for NgCAM-GFP (Burack et al., 2000) . Although 0N4Rtau-EGFP is present in the dendrites, showing the usual thicker, more tapered process morphology compared with axons, it is clear that the 0N4Rtau-EGFP present in the axons is clearly identifiable, given the thinner uniform morphology of the process and the lack of staining for MAP2. This method is therefore a legitimate neuronal model in which to study the axonal transport of tau-EGFP, and all of the measurements of axonal transport of tau were made on the longest and thinnest process because this is most likely the axon of the studied cells.
Axonal transport of tau is an energy-dependent process
To assess the requirement for metabolic energy for the transport of tau, we incubated cells with 2-deoxy-D-glucose/sodium azide, which is known to inhibit energy-dependent metabolic processes (Yoon et al., 1998) (Fig. 3) . The transport of 0N4Rtau-EGFP was halted after the deoxyglucose treatment; after the inhibitors were washed out, the transport rate resumed at a rate comparable with that of untreated cells, showing that the cessation of tau transport because of the inhibition of metabolic processes was reversible on removal of the treatment and that no subsequent detrimental effect on tau transport was observed.
The average distance traveled by tau-EGFP at the first time point that was analyzed differed by ϳ0 -20 m between experiments. These differences are attributed to the small variations in the time of expression of the recombinant protein after transfection (Ackerley et al., 2000) . To facilitate comparisons among the experimental data shown in Figures 3, 4 , 6, and 7, we have depicted the distance traveled as the distance from the first measurement, which is recorded as zero.
Incorporation or position of the EGFP tag on the tau molecule does not affect the transport of tau
We investigated whether the inclusion or position of the EGFP tag affected the rate of transport of transfected tau. The transport of untagged 0N4Rtau expressed in pCIneo was compared with that of 0N4Rtau-EGFP (Fig. 4) . Figure 4 A shows representative images of untagged 0N4Rtau transported along the neurites. Neurons that were transfected with 0N4Rtau-pCIneo were fixed and stained with a 4Rtau-specific antibody and were analyzed in an identical way to those transfected with 0N4Rtau-EGFP (Fig.  4 B) . The overall slow rate of axonal transport of untagged 0N4Rtau was 0.873 Ϯ 0.005 mm/d compared with 0.916 Ϯ 0.035 mm/d for 0N4Rtau-EGFP (not significantly different with oneway ANOVA test; p ϭ 0.3).
The overall rate of tau transport was not affected by the position of the EGFP tag because the average rate of transport of 0N4Rtau-EGFP expressed in pEGFP-N1 (tau tagged with GFP at its C terminus) was comparable with that expressed in pEGFP-C1, i.e., N-terminally tagged [N1 ϭ 1.030 Ϯ 0.028 mm/d (data not shown); C1 ϭ 1.003 Ϯ 0.093 mm/d (not significantly different with one-way ANOVA test; p ϭ 0.8)].
Axonal tau-EGFP is present as both a microtubulebound and a soluble fraction
Because tau exists in neurons in at least two compartments, microtubule-bound and soluble tau, it was important to determine whether bound and soluble tau might be transported at different rates. This was investigated by making measurements of neurons fixed in ways so that these two different compartments might be distinguished. Thus a range of fixation/extraction/permeabiliza- tion procedures was compared, and the distances traveled by 0N4Rtau-EGFP 310 min after transfection were determined. With procedure 1 involving fixation only with PFA, the average distance traveled by 0N4Rtau-EGFP was 197.2 m (Ϯ 11.2). With the use of procedures 2, 3, and 4 involving fixation with PFA followed by permeabilization with 0.1% (v/v) Triton X-100 for 2 or 10 min and 0.5% (v/v) Triton X-100 for 10 min, respectively, the average distance traveled was 203.67 m (Ϯ 21.2), 207.53 m (Ϯ 12.4), and 194.23 m (Ϯ 15.2). With the use of procedure 5 involving fixation with glutaraldehyde without extraction followed by permeabilization with Triton X-100, the average distance traveled was 194.75 m (Ϯ 14.8). With the use of procedure 6 involving a combined fixation/extraction step, the average distance traveled was 197.14 m (Ϯ 8.1). Fixation methods followed by permeabilization (procedures 2, 3, 4, and 5) did not alter the measured distance that 0N4Rtau-EGFP traveled as assessed after fixation alone. When unbound tau was extracted (procedure 6), the measured distance traveled by the tau-EGFP was statistically no different from when unbound tau was still present. This indicates in our experimental system that a portion of tau-EGFP within the axon is microtubule bound but that unbound tau apparently is not transported at a faster rate than that associated with microtubules.
It was important to verify that the fixation/extraction procedure 6 indeed did behave as reported by Black et al. (1996) under our experimental conditions. Therefore, 0N4Rtau-EGFPtransfected neurons either were fixed by procedure 1 or fixed/ extracted by procedure 6 and then processed by immunofluorescence for tubulin staining (24 hr after transfection). Figure 5a shows EGFP-tagged tau labeling of a neuron fixed by procedure 1 (Fig. 5b shows the corresponding tubulin stain) . The diffuse fluorescence of tau-EGFP in Figure 5 is likely to be attributable to the presence of both cytoplasmic and microtubule-bound tau. By contrast, after fixation/extraction by procedure 6 the tau-EGFP appears to colocalize with microtubules (Fig. 5c,d) , shown by the sharp filamentous tau-EGFP fluorescence within some of the neuronal processes. The sharper tau-EGFP fluorescence in neurons processed by procedure 6 is evident probably because the cytoplasmic tau was removed, as shown by Black et al. (1996) . To confirm this interpretation, we treated neurons with nocodazole, a microtubule-depolymerizing drug, and then processed them by the fixation/extraction procedure 6 (Fig. 5e,f ) . Tau-EGFP fluorescence and tubulin immunofluorescence virtually were abolished, indicating that after microtubule depolymerization fixation/extraction procedure 6 removed most of the tau and tubulin. Thus under conditions in which microtubules remained assembled, only unbound cytoplasmic tau was extracted (Fig. 5c,d ). This was confirmed biochemically; neurons were treated with or without the extraction component of procedure 6 [0.5% (v/v) NP-40], and any extracted protein was precipitated and analyzed by immunoblotting for tau (Fig. 5g) . Without the extraction detergent nearly all tau protein remained within the cell lysate, as expected (Fig. 5g, lanes 1, 2) . However, after incubation with the extraction detergent a considerable proportion of tau was extracted into the solution (Fig. 5g, lanes 3, 4 ) . (Immunoblotting was repeated as above with cells processed with the complete fixation/ extraction solution; because of the smeary nature of the gels caused by the analysis of fixed cells by SDS-PAGE, these data are not shown, although the profile of the tau extracted from the cells was the same as that shown in Fig. 5g ). These results confirm that fixation/extraction procedure 6 does remove cytoplasmic tau, with the unextracted tau being colocalized, i.e., bound, to the microtubules (Fig. 5c,d) .
Presence of N-terminal inserts and the exon 10 C-terminal repeat have no significant effect on the rate of tau transport
We next compared the overall slow rate of anterograde axonal transport of the following wild-type tau isoforms: 0N3R, 0N4R, 2N3R (2 N-terminal insert, 3 C-terminal repeat tau isoform), and 2N4Rtau (2 N-terminal insert, 4 C-terminal repeat tau isoform) all tagged with EGFP (Fig. 6) . The data shown are from three to five independent experiments; error bars indicate SEM. Within each experiment 20 -50 neurites were measured for each data point. The overall slow rate of axonal tau transport was determined by averaging the rate generated by linear regression for each experimental data set. When we compared different isoforms of tau, the overall rate of transport for 0N3Rtau-EGFP was 0.965 Ϯ 0.157 mm/d; for 2N3Rtau-EGFP it was 0.931 Ϯ 0.071 mm/d; for 0N4Rtau-EGFP it was 0.952 Ϯ 0.064 mm/d; for 2N4Rtau-EGFP it was 0.927 Ϯ 0.082 mm/d. The axonal transport rate of tau determined by this method was comparable with that classically known as the slow transport component as measured in vivo. No statistically significant differences in the overall slow rate of axonal transport of tau containing either zero or two N-terminal inserts or three or four C-terminal repeats were seen (not significantly different with one-way ANOVA test; p Ͼ 0.4 for comparisons of 0N3R to 0N4R, 0N3R to 2N3R, and 0N4R to 2N4R).
Mutations found in FTDP-17 have no observable effect on the rate of tau transport
We compared the overall rate of axonal transport of EGFPtagged wild-type tau and a variety of mutant EGFP-tagged tau species found in FTDP-17. Figure 7a -c shows a comparison among wild-type 0N3Rtau-EGFP, 0N4Rtau-EGFP, and the tau-EGFP species bearing the following FTDP-17 mutations: 0N3Rtau-V337M, 0N3Rtau-R406W, 0N4Rtau-I260V, 0N4Rtau-delK280, 0N4Rtau-P301L, 0N4Rtau-V337M, and 0N4Rtau-R406W. Figure 7d shows the overall slow transport rates of all of the tau species that were analyzed. The average rate of tau transport for 0N3Rtau was 1.128 Ϯ 0.084 mm/d; 0N3R-V337M was 1.154 Ϯ 0.095 mm/d; 0N3R-R406W was 1.111 Ϯ 0.131 mm/d; 0N4Rtau was 1.003 Ϯ 0.093 mm/d; 0N4R-I260V was 1.138 Ϯ 0.113 mm/d; 0N4R-delK280 was 1.192 Ϯ 0.122 mm/d; 0N4R-P301L was 1.133 Ϯ 0.107 mm/d; 0N4R-V337M was 1.174 Ϯ 0.067 mm/d; 0N4R-R406W was 1.026 Ϯ 0.085 mm/d (independent experiment number, n, ϭ 4 -10). No significant differences in the overall slow rate of axonal transport of tau, either wild-type or tau bearing FTDP-17 mutations, were seen (not significantly different with one-way ANOVA test; p Ͼ 0.3 for comparisons of wild-type tau to mutated tau).
DISCUSSION
Aberrant deposition of tau in neurons, much of it perikaryal, typifies the tauopathies, but the mechanisms underlying this deposition are unknown. One possible mechanism is the disruption of axonal transport such that tau would accumulate in the cell body. After injection with A␤ 42 fibrils, enhanced tau pathology was observed in transgenic mice expressing mutant tau (Götz et al., 2001) . Given the anatomical separation of amyloid deposition and tangle formation, it was suggested that amyloid fibrils impaired the axonal transport of tau (Götz et al., 2001) . In other studies overexpression of the smallest isoform of tau in transgenic mice resulted in tau inclusions and reduced fast axonal transport of organelles (Ishihara et al., 1999) , and overexpression of tau in both neuronal and non-neuronal cells also reduced kinesindependent fast transport of vesicles, neurofilaments, and mito- chondria (Ebneth et al., 1998; Trinczek et al., 1999; Stamer et al., 2002) . Disruption of axonal transport in neurodegenerative disease is therefore a mechanism worthy of further exploration, particularly because the slowing of neurofilament transport is an early pathological feature of amyotrophic lateral sclerosis (ALS) (Collard et al., 1995; Zhang et al., 1997; Williamson and Cleveland, 1999 ) and mutated kinesin isoforms have been shown to underlie human peripheral neuropathy (Zhao et al., 2001) . Overexpression of APPL, the Drosophila homolog of APP, also has been shown to disrupt axonal transport (Torroja et al., 1999) . Based on studies of transgenic mice and Drosophila, it also has been suggested that disturbed axonal transport of amyloid precursor protein (APP) and apolipoprotein E contribute to neuronal death in these models and hence in Alzheimer's disease (Tesseur et al., 2000; Gunawardena and Goldstein, 2001 ).
Brain tau exists as six alternatively spliced isoforms; to date, five splice site mutations, 14 missense mutations, and a 3 bp deletion have been identified in Ͼ50 FTDP-17 families (for review, see Goedert et al., 1998; van Slegtenhorst et al., 2000) . The splice site mutations lead to an overproduction of four-repeat tau, implying the importance of maintaining tight ratios of threeto four-repeat tau for a functional system (Hutton et al., 1998; Spillantini et al., 1998; Varini et al., 1999) . We therefore set out to investigate the transport characteristics of different tau isoforms and certain mutants in a cultured neuronal system developed in our laboratory (Ackerley et al., 2000) . This system has certain advantages over animal studies and is more versatile. Individual tau species, including mutants, can be followed in the presence of endogenous tau by appropriate tagging, and the experiments can be conducted quickly and efficiently, unlike time-consuming in vivo transport studies that would require numerous transgenic animals to be generated.
Using this experimental system, we have demonstrated that the EGFP-tagged tau is localized in axons, although it is also present in dendrites. Our data on comparing different fixation/extraction protocols demonstrate that a portion of the tau-EGFP expressed within the axons is microtubule bound and that soluble tau apparently was not transported at a faster rate than microtubulebound tau. Unlike Aronov et al. (2001) , we did not confirm the requirement of a 3Ј-untranslated region for axonal targeting and conclude that this may be restricted to certain neuronal cell types, because they studied differentiated P19 embryonic carcinoma cells. We found that the presence of an EGFP tag had no effect on the slow transport rate of tau; hence these constructs do seem to be valid tools for studying tau transport. The slow transport of tau was shown to be energy-dependent, as we had shown previously was the case for slow transport of neurofilaments and ␣-synuclein The overall anterograde transport of tau was found by this method to be ϳ1 mm/d, which corresponds with the reported rate for the slow component a of axonal transport. This rate differs from those initially reported in the literature, measuring in vivo transport of tau by radioisotopic labeling, of 0.2-0.4 mm/d in retinal ganglion cells. It is well known that variation in the transport rate of proteins has been observed between different cell types (Galbraith and Gallant, 2000) , and, given the different methodology used here and the fact that tau transport in cortical neurons has not been reported, it is not unexpected to observe different overall rates of transport from those previously reported in vivo.
Functional differences between 3Rtau and 4Rtau isoforms have been demonstrated in a number of studies both in vitro and in cells. For example, 4Rtau binds to microtubules with higher affinity than 3Rtau (Butner and Kirschner, 1991; Gustke et al., 1994; Ackmann et al., 2000) , and the inter-repeat regions of 3R and 4Rtau may act in part by distinct molecular mechanisms (Goode et al., 2000) . It also appears that 3Rtau may be more susceptible to oxidative stress both in vitro and in cells, again highlighting functional differences between the isoforms under certain conditions (Utton et al., 2001) . So far, however, no functional differences between tau isoforms with 0N, 1N, or 2N-terminal inserts have been described. We therefore investigated whether variation in either the number of C-terminal repeats or N-terminal inserts and the mutants of tau might affect tau transport.
Our results show that none of these intrinsic variants of tau have any effect on tau transport, which is an important observation because reduced transport from the cell body could account for the accumulation of perikaryal tau and hence inclusion body formation in the tauopathies. In the case of tau it is more likely, therefore, that excesses of either 4Rtau or 3Rtau in FTDP-17 and Pick's disease or mutant forms of tau affect other properties such as differences in microtubule dynamic properties (for review, see Lee et al., 2001 ). However, Götz et al. (2001) have suggested that extracellular A␤ 42 fibrils may cause a reduction in axonal transport because the presence of tangles in a transgenic mouse with mutant tau is anatomically remote from the A␤ deposits. Axonal transport of tau therefore still may be important in the tauopathies because an imbalance of tau isoforms or the presence of mutant taus may render tau more susceptible to extraneous factors that reduce transport rates; these could include A␤ deposits and oxidative stress. The experimental system that we have described herein is therefore likely to prove to be a powerful new tool to investigate putative pathogenic mechanisms for these diseases.
